The observation that Aza treatment in our model enhanced CD4+ and CD8+ T cell infiltration and caused significant, and in some cases complete, tumor regression without the need for checkpoint blockade or additional therapies, indicates that PDAC patients may benefit from the use of DNMT inhibitors as single agents. This evidence concerns the gene DNMT1 and neoplasm.